Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $90.7M | $93.5M | $78.6M | $90.9M | $78.9M | $131M | $128M | $201M | $154M | $160M |
| Revenue growth | — | 3.0% | -15.9% | 15.6% | -13.2% | 65.4% | -1.7% | 56.3% | -23.2% | 3.9% |
| Gross profit | $44.2M | $34.7M | $25.1M | $34.6M | $32.6M | $58.9M | $49.0M | $52.8M | $37.3M | $45.8M |
| Gross margin | 48.7% | 37.1% | 31.9% | 38.0% | 41.3% | 45.1% | 38.2% | 26.3% | 24.2% | 28.6% |
| Operating income | -$71.2M | -$89.8M | -$101M | -$101M | -$104M | -$210M | -$307M | -$334M | -$474M | -$554M |
| Operating margin | -78.5% | -96.1% | -128.4% | -110.6% | -132.3% | -161.2% | -239.4% | -166.8% | -308.0% | -346.2% |
| Net income | -$74.4M | -$92.2M | -$103M | -$84.1M | $29.4M | -$181M | -$314M | -$307M | -$310M | -$546M |
| Net margin | -82.0% | -98.6% | -130.4% | -92.6% | 37.3% | -138.9% | -244.9% | -153.0% | -201.2% | -341.5% |
| EPS (diluted) | -$0.83 | -$0.87 | -$0.76 | -$0.55 | $0.17 | -$0.89 | -$1.40 | -$1.21 | -$1.59 | -$1.82 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$67.9M | -$67.5M | -$66.4M | -$78.3M | $19.5M | -$111M | -$263M | -$259M | -$206M | -$111M |
| Capital expenditures | $8.21M | $10.4M | $1.85M | $2.84M | $1.04M | $5.93M | $16.8M | $8.84M | $6.19M | $2.71M |
| Free cash flow | -$76.1M | -$78.0M | -$68.3M | -$81.1M | $18.5M | -$117M | -$280M | -$268M | -$212M | -$114M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $16.8M | $16.5M | $18.8M | $29.6M | $81.6M | $461M | $325M | $180M | $55.4M | $63.7M |
| Total assets | $138M | $144M | $170M | $148M | $414M | $2.01B | $1.77B | $1.75B | $1.26B | $784M |
| Total liabilities | $53.2M | $58.0M | $56.2M | $93.1M | $78.5M | $1.22B | $1.20B | $1.04B | $754M | $779M |
| Long-term debt | $16.1M | $13.6M | $14.7M | $15.9M | — | $896M | $897M | — | — | — |
| Shareholders' equity | $84.7M | $86.1M | $114M | $54.9M | $335M | $791M | $563M | $701M | $507M | $5.35M |
| Retained earnings | -$788M | -$880M | -$982M | -$1.07B | -$1.04B | -$1.22B | -$1.53B | -$1.84B | -$2.15B | -$2.70B |
| Shares (wtd avg diluted) | 92.7M | 116M | 135M | 153M | 175M | 204M | 225M | 254M | 288M | 300M |
Every figure is extracted from PACIFIC BIOSCIENCES OF CALIFORNIA, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.